Immune checkpoint inhibitors (ICI) are shown to increase survival in patients with advanced non-small cell-lung cancer (aNSCLC) and good Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–1, as compared to standard chemotherapy in the second-line setting [1,2,3,4], and as front-line therapy for patients with programmed cell death ligand one (PD-L1) expression in ≥50% tumor cells [5]. Here, CD274 is linked to neoplasm.